- Cambium Plant Sciences to disrupt cannabis industry through the
development and licensing of next generation cannabis plant
genetics and cultivation IP.
- Supreme Cannabis will invest approximately $14 million for the construction of a
state-of-the-art, 34,000 sqft research and development facility
located in Goderich, Ontario.
TORONTO, April 22, 2019 /CNW/ - The Supreme Cannabis
Company, Inc. ("Supreme Cannabis" or the "Company") (TSX: FIRE)
(OTCQX: SPRWF) (FRA: 53S1), today announced the launch of Cambium
Plant Sciences ("Cambium"), located in Goderich, Ontario. Cambium, a wholly-owned
subsidiary of Supreme Cannabis, aims to lead the agricultural
revolution of cannabis genetics, redefining consumer experiences
and cultivation economics across the global cannabis industry.
With the systematic application of research, technology and
science, Cambium will focus on developing the next generation of
premium cannabis genetics for recreational, medical and wellness
applications. Cambium's innovative mission is to supply
agriculturally-focused, disease resistant, premium seed stock to
the rapidly growing global cannabis market.
"Our proprietary genetics selection methodology and ability to
cultivate high-end cannabis at scale at 7ACRES has created strong
industry demand for our proprietary genetics and cultivation
techniques. It was as a result of the demand that we saw a global
opportunity to create a company whose sole focus is innovating
plant genetics and cultivation IP for the global cannabis market.
We believe genetics are the foundation of proprietary cannabis
products in the long term," said Navdeep
Dhaliwal, CEO of Supreme Cannabis. "Cambium will develop
cultivars that benefit our in-house brands, as well as our domestic
and global cultivation and manufacturing partners. Initially,
Cambium is expected to benefit from 7ACRES' established genetics,
existing infrastructure and the unparalleled plant knowledge of its
team."
Leading Cambium as General Manager is Dr. Alan Darlington. Dr. Darlington joined Supreme
Cannabis' wholly-owned subsidiary, 7ACRES as the Director of
Special Projects, where he has been successful in improving the
agricultural performance of 7ACRES' award winning genetics. Dr.
Darlington holds a PhD from the University of
Guelph in greenhouse systems and has over 30 years of
experience leading and working with diverse multidisciplinary teams
to develop plant-based IP.
"Cannabis has not yet had the benefit of the agricultural
revolution that transformed commercial agriculture on a global
scale over the past century. We believe, Cambium will play a
leading role in advancing the cannabis industry by revolutionizing
strain development to enhance the broader industry's outputs," said
Dr. Alan Darlington, General Manager
of Cambium. "From the next blockbuster recreational strain, to
disease resistant agricultural seed stock, Cambium will seek to
improve the economic profile of cannabis production by pushing the
boundaries of the cannabis plant."
Supreme Cannabis will invest approximately $14 million to develop a world leading facility
for cannabis-focused research and innovation. The Cambium facility
will include the development of proprietary growing rooms for
testing and selection of new genetics, breeding rooms for the
creation of new seed stock, and supporting infrastructure in the
existing 34,000 sqft facility. Supreme Cannabis expects to commence
the retrofitting of the Cambium facility in the early summer of
2019 and Cambium has commenced the Health Canada licensing
process.
For more information on Cambium Plant Sciences, visit website or
on Instagram, Twitter, and Facebook.
About Supreme Cannabis
The Supreme Cannabis Company, Inc., is a global diversified
portfolio of distinct cannabis companies, products and brands.
Since 2014, the Company has emerged as one of the world's
fastest-growing, premium plant driven-lifestyle companies by
effectively deploying capital, with an emphasis on disciplined
growth and high-quality products.
Supreme Cannabis' portfolio includes 7ACRES, its wholly-owned
subsidiary and multi-award-winning brand; Cambium Plant Sciences, a
plant genetics and cultivation IP company; Medigrow Lesotho, a
cannabis oil producer located in southern Africa; and a brand partnership and licensing
deal with Khalifa Kush Enterprises Canada.
Supreme trades as FIRE on the Toronto Stock Exchange (TSX:
FIRE), SPRWF on the OTC Exchange in the
United States (OTCQX: SPRWF) and 53S1 on the Frankfurt Stock
Exchange (FRA: 53S1). Follow us on Instagram, Twitter,
Facebook and YouTube.
We simply grow better.
Forward-Looking Information
Certain statements made in this press release may constitute
forward-looking information under applicable securities laws. These
statements may relate to anticipated events or results and include,
but are not limited to, the results and benefits of Cambium Plant
Sciences' work, the conversion of the Goderich facility and other statements that
are not historical facts. Particularly, information regarding our
expectations of future results, targets, performance achievements,
prospects or opportunities is forward-looking information. Often,
but not always, forward-looking statements can be identified by the
use of forward-looking terminology such as "may", "will", "expect",
"believe", "estimate", "plan", "could", "should", "would",
"outlook", "forecast", "anticipate", "foresee", "continue" or the
negative of these terms or variations of them or similar
terminology. Forward-looking statements are current as of the date
they are made and are based on applicable estimates and assumptions
made by us at the relevant time in light of our experience and
perception of historical trends, current conditions and expected
future developments, as well as other factors that we believe are
appropriate and reasonable in the circumstances. However, we do not
undertake to update any such forward-looking information whether as
a result of new information, future events or otherwise, except as
required under applicable securities laws in Canada. There can be no assurance that such
estimates and assumptions will prove to be correct. Many
factors could cause our actual results, level of activity,
performance or achievements or future events or developments to
differ materially from those expressed or implied by the
forward-looking statements, including, without limitation, the
factors discussed in the "Risk Factors" section of the Company's
Annual Information Form dated October 2,
2018 ("AIF"). A copy of the AIF and the Company's other
publicly filed documents can be accessed under the Company's
profile on the System for Electronic Document Analysis and
Retrieval ("SEDAR") at www.sedar.com. The Company cautions that the
list of risk factors and uncertainties described in the AIF is not
exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking information
and are cautioned not to place undue reliance on such
information.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/supreme-cannabis-launches-cannabis-genetics-company-cambium-plant-sciences-300834784.html
SOURCE The Supreme Cannabis Company, Inc.